Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Cognition Therapeutics ( (CGTX) ) is now available.
On December 18, 2025, Cognition Therapeutics entered into a new Open Market Sale Agreement with Jefferies LLC to establish an at-the-market equity offering of up to $75 million of its common stock, under which Jefferies will act as sales agent or principal and receive a 3% commission on any shares sold. In conjunction with this new facility, the company terminated its prior at-the-market sales agreement with Cantor Fitzgerald and B. Riley Securities, effective December 18, 2025, leaving roughly $12.5 million of capacity unused under the 2022 program and signaling a shift of its equity capital-raising activities to the new Jefferies-managed structure without incurring termination penalties.
The most recent analyst rating on (CGTX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Cognition Therapeutics stock, see the CGTX Stock Forecast page.
Spark’s Take on CGTX Stock
According to Spark, TipRanks’ AI Analyst, CGTX is a Neutral.
Cognition Therapeutics is currently facing major financial challenges with persistent losses and cash flow issues. Technical indicators provide mixed signals with short-term momentum but long-term caution. Valuation remains a concern with negative earnings and no dividend yield. Although the earnings call highlighted some strategic progress, significant concerns like NASDAQ compliance and uncertain funding overshadow these advancements. Overall, the stock is a high-risk investment with potential for future improvement if financial and strategic objectives are met.
To see Spark’s full report on CGTX stock, click here.
More about Cognition Therapeutics
Cognition Therapeutics, Inc. is a publicly traded biopharmaceutical company that issues common stock to fund its operations and strategic initiatives, using at-the-market equity offerings as a recurring capital-raising mechanism.
Average Trading Volume: 1,417,799
Technical Sentiment Signal: Buy
Current Market Cap: $134.2M
Find detailed analytics on CGTX stock on TipRanks’ Stock Analysis page.